In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her passion for tobacco control and the importance of open-access journals in elevating research globally. Read more
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning. Read more
During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more
During TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression. Read more
Revisit all your favorite moments from #TTLC23 in our photo gallery. Read more
In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC. Read more
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?
+more
Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials. Read more
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN. Read more
Studies that don’t show survival benefit with more frequent surveillance won’t convince patients they’re better off without scans. Even if regularly scheduled scans don’t help patients live longer, they do help them live better. Read more
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership. Read more